This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
by Zacks Equity Research
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.85% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions
by Zacks Equity Research
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Integer (ITGR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 1.79% and 0.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
by Zacks Equity Research
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
TMO vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Idexx Laboratories (IDXX) concluded the recent trading session at $519.81, signifying a +0.99% move from its prior day's close.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy
by Zacks Equity Research
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.